3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
5756
Lung Neoplasms
3723
Small Cell Lung Carcinoma
1021
Breast Neoplasms
668
Neoplasms
615
Colorectal Neoplasms
560
Melanoma
479
Ovarian Neoplasms
435
Neoplasm Metastasis
431
Pancreatic Neoplasms
386
Stomach Neoplasms
332
Carcinoma, Renal Cell
312
Adenocarcinoma of Lung
309
Squamous Cell Carcinoma of Head and Neck
306
Head and Neck Neoplasms
294
Prostatic Neoplasms
285
Mesothelioma, Malignant
281
Esophageal Neoplasms
266
Mesothelioma
244
Colonic Neoplasms
225
Brain Neoplasms
217
Urinary Bladder Neoplasms
212
Triple Negative Breast Neoplasms
211
Uterine Cervical Neoplasms
209
Endometrial Neoplasms
175
Sarcoma
171
Carcinoma, Hepatocellular
159
NSCLC
136
Carcinoma
128
Kidney Neoplasms
127
Interventions
osimertinib
1
Gefitinib
1
Erlotinib Hydrochloride
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
×
Thoracic
×
Clear all
NCT02296125
2026-04-21
FLAURA
AstraZeneca
Phase 3
Completed
674 enrolled
21 charts
1 FDA